FY2027 Outlook • CSL is positioned for a return to sustainable growth, supported by solid underlying market fundamentals, a simplified business and targeted investment in our commercial capabilities. • CSL Behring expects mid single digit revenue growth on a constant currency basis with Ig growth at mid to high single digits in line with the market. • CSL Seqirus expects low single digit revenue growth. Immunisation rates in the United States are anticipated to decline, but at a slower rate than recent seasons. • CSL Vifor will continue to be impacted by generic competition in iron products and the withdrawal of TAVNEOS® in EU markets. US$ millions reported CSL Behring FY26 CSL Vifor FY26 CSL Seqirus FY26 Sales 11,087 2,316 1,809 Other Revenue 300 63 222 Total Revenue 11,387 2,379 2,031 Gross Profit1 5,648 1,655 1,151 GP %1 49.6% 69.6% 56.7% Sales & Marketing (1,036) (403) (252) Operating Result1 4,612 1,252 899 Operating Segment %1 40.5% 52.6% 44.3% US$15.8b in annual revenue Overview Despite a challenging 12 months, CSL has taken decisive action to create a clear path to return to sustainable growth. The underlying market fundamentals and demand for plasma remains robust and there is strong momentum behind newer therapies such as ANDEMBRY® and HEMGENIX®. CSL Seqirus continued to gain share in a difficult influenza market and CSL Vifor was impacted by competition from generic iron products. CSL made solid progress on its transformation program and it continued to simplify the business and invest in its commercial capabilities. Strong cash flow from operations and a robust balance sheet allowed the company to announce a further A$1.15 billion share buy-back program. 1. Underlying results have been adjusted to exclude the impacts from the amortisation of acquired IP and significant non-recurring items including those related to one-off restructuring and impairments expenses, business acquisitions and disposals. Segment Financial highlights CSL Vifor FY2027 Outlook • Increased competition from generic products in iron. • Focus on expanding patient access across iron and rare nephrology portfolio to address unmet need and rising chronic disease burden in conditions like iron deficiency and anaemia. • Continue to launch and drive adoption of FILSPARI® in IgAN. • TAVNEOS® withdrawal in EU and EEA countries. Ongoing engagement with regulatory authorities (exclusive of US and Singapore) with respect to questions around data integrity of the ADVOCATE study. • Collaboration across CSL to strengthen capabilities and operational efficiency. US$2,379m CSL Vifor revenue Overview CSL Vifor continues to be a key player in the iron deficiency market with FERINJECT® and continues to expand its nephrology portfolio through the launch of FILSPARI® for rare kidney disease. With growing unmet need driven by chronic disease and ageing populations, the business continued to expand patient access and achieve key regulatory milestones. FY2026 Highlights • FERINJECT® expansion across geographies and treatment settings. • Expanded and commercialised the nephrology portfolio with FILSPARI® and KAPRUVIA® to treat kidney diseases. • Achieved a key regulatory milestone for FILSPARI® in Europe, with conversion from conditional to standard marketing authorisation for a condition called IgA nephropathy, supporting broader patient access across key markets. • Expanded diagnosis and treatment of kidney diseases and related disorders, including chronic kidney disease. • Continued geographic expansion and product label enhancements. 13 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3